IDEXX Laboratories Management
Management criteria checks 3/4
IDEXX Laboratories' CEO is Jay Mazelsky, appointed in Jun 2019, has a tenure of 6.33 years. total yearly compensation is $13.01M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth $52.04M. The average tenure of the management team and the board of directors is 0.8 years and 8.6 years respectively.
Key information
Jay Mazelsky
Chief executive officer
US$13.0m
Total compensation
| CEO salary percentage | 8.62% |
| CEO tenure | 6.3yrs |
| CEO ownership | 0.1% |
| Management average tenure | less than a year |
| Board average tenure | 8.6yrs |
Recent management updates
Recent updates
IDEXX Laboratories: Recurring Revenue And Market Moat - Why I Choose To Buy
Oct 02Earnings Not Telling The Story For IDEXX Laboratories, Inc. (NASDAQ:IDXX) After Shares Rise 25%
Aug 16
IDEXX Laboratories, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 07At US$532, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?
Jul 23IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable
May 11IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) CEO Compensation Looks Acceptable To Us And Here's Why
May 01Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth US$427 Based On Its Intrinsic Value?
Apr 24IDEXX Laboratories: I Love The Business, Not The Stock Price
Apr 14We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
Mar 30IDEXX Laboratories: A Top Dog In The Pet Care Market
Mar 12IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Business Is Yet to Catch Up With Its Share Price
Feb 27IDEXX Laboratories And Its Real Value
Feb 10Calculating The Fair Value Of IDEXX Laboratories, Inc. (NASDAQ:IDXX)
Jan 13IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 26At US$420, Is It Time To Put IDEXX Laboratories, Inc. (NASDAQ:IDXX) On Your Watch List?
Nov 19IDEXX Laboratories Q3: Weak End-Market Demand Continues
Nov 11Investors Appear Satisfied With IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Prospects
Oct 28Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 15
Global Expansion And Innovative Products Propel Revenue And Margin Growth Amidst Challenges
IDEXX's international and innovative product growth, like the inVue Dx Cellular Analyzer, fuels potential revenue and market share increases globally.IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits
Aug 12Looking For Fast Growth In Healthcare? IDEXX Has You Covered
Jun 28IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)
Apr 08IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified
Jan 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | US$986m |
| Mar 31 2025 | n/a | n/a | US$895m |
| Dec 31 2024 | US$13m | US$1m | US$888m |
| Sep 30 2024 | n/a | n/a | US$866m |
| Jun 30 2024 | n/a | n/a | US$846m |
| Mar 31 2024 | n/a | n/a | US$867m |
| Dec 31 2023 | US$12m | US$1m | US$845m |
| Sep 30 2023 | n/a | n/a | US$823m |
| Jun 30 2023 | n/a | n/a | US$791m |
| Mar 31 2023 | n/a | n/a | US$699m |
| Dec 31 2022 | US$10m | US$1m | US$679m |
| Sep 30 2022 | n/a | n/a | US$670m |
| Jun 30 2022 | n/a | n/a | US$664m |
| Mar 31 2022 | n/a | n/a | US$735m |
| Dec 31 2021 | US$9m | US$977k | US$745m |
| Sep 30 2021 | n/a | n/a | US$757m |
| Jun 30 2021 | n/a | n/a | US$728m |
| Mar 31 2021 | n/a | n/a | US$674m |
| Dec 31 2020 | US$7m | US$814k | US$582m |
| Sep 30 2020 | n/a | n/a | US$497m |
| Jun 30 2020 | n/a | n/a | US$460m |
| Mar 31 2020 | n/a | n/a | US$437m |
| Dec 31 2019 | US$7m | US$632k | US$428m |
| Sep 30 2019 | n/a | n/a | US$423m |
| Jun 30 2019 | n/a | n/a | US$407m |
| Mar 31 2019 | n/a | n/a | US$390m |
| Dec 31 2018 | US$3m | US$555k | US$377m |
Compensation vs Market: Jay's total compensation ($USD13.01M) is about average for companies of similar size in the US market ($USD13.26M).
Compensation vs Earnings: Jay's compensation has been consistent with company performance over the past year.
CEO
Jay Mazelsky (64 yo)
Mr. Jonathan J. Mazelsky, also known as Jay, serves as Independent Director at DENTSPLY SIRONA Inc. since May 24, 2023. He has been President, Chief Executive Officer and Director at IDEXX Laboratories, In...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.3yrs | US$13.01m | 0.10% $ 52.0m | |
| Executive VP and GM Global Reference Laboratories | 5.8yrs | US$3.73m | 0.0097% $ 4.9m | |
| Executive Vice President of Global Strategy & Commercial | less than a year | US$3.73m | 0.023% $ 11.5m | |
| Executive Vice President of Global Operations and R&D | less than a year | US$3.72m | 0.0017% $ 878.7k | |
| Executive VP | less than a year | no data | 0.0048% $ 2.4m | |
| Senior Vice President of Global Operations | less than a year | no data | no data | |
| Executive VP | no data | US$1.88m | 0.0079% $ 4.0m | |
| Senior VP & Global Marketing Officer | less than a year | no data | no data | |
| Executive VP & Chief Human Resources Officer | 3.6yrs | no data | 0.0030% $ 1.5m | |
| Executive Vice President of Global CAG Commercial | less than a year | no data | 0.010% $ 5.3m | |
| Senior Vice President of Commercial Finance & Sales Operations | 1.8yrs | no data | no data | |
| Executive VP and GM of Point of Care Diagnostics & Telemedicine | no data | no data | 0.014% $ 7.1m |
Experienced Management: IDXX's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6yrs | US$13.01m | 0.10% $ 52.0m | |
| Independent Director | 13.3yrs | US$372.38k | 0.0022% $ 1.1m | |
| Independent Director | 11.6yrs | US$369.88k | 0.0041% $ 2.1m | |
| Independent Director | 10.3yrs | US$356.10k | 0.0022% $ 1.1m | |
| Independent Director | 8.3yrs | US$354.88k | 0.0028% $ 1.4m | |
| Independent Director | less than a year | no data | no data | |
| Independent Non-Executive Chairman | 9yrs | US$499.94k | 0.010% $ 5.2m | |
| Independent Director | 12.3yrs | US$339.88k | 0.011% $ 5.5m | |
| Independent Director | 2.3yrs | US$363.65k | 0.00026% $ 131.3k | |
| Independent Director | 6.3yrs | US$347.38k | 0% $ 0 |
Experienced Board: IDXX's board of directors are considered experienced (8.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/06 16:29 |
| End of Day Share Price | 2025/10/06 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IDEXX Laboratories, Inc. is covered by 31 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Owczarski | Avondale Partners |
| Ishan Majumdar | Baptista Research |
| Navann Ty Dietschi | BNP Paribas Exane |